Hims Review
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Quick Verdict
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Who it's for: Hims is best suited to buyers who want a recognizable, publicly traded telehealth platform with broad category coverage and no insurance hassles. The proprietary MedMatch personalization layer matters most to people who plan to stay on the platform across multiple conditions.
Bottom line: A high-volume operator with one of the widest formularies in telehealth, useful for buyers who want a single login across categories. Look elsewhere if you want a boutique clinic relationship or specialist-grade depth in any one vertical.
Compare Hims on price, review history, and fit
Hims may be a strong fit. Before enrolling, compare its published details with three reviewed alternatives. Some links are compensated; editorial scores are independent.
| Provider | Published price | Trustpilot |
|---|---|---|
| WellMedr | From $49 – $129/mo | 4.6/5 (1,963) |
| Trimi | From $99 – $125/mo | Not listed |
| SkinnyRx | From $149 – $449/mo | 4.8/5 (5,335) |
- Both compounded and brand-name GLP-1 access
- Single account spans weight loss, ED, and hair
- Public-company transparency on financials
- Insurance not accepted
- Subscription auto-renewal model
- State availability varies by program
Pros & Cons In Detail
Compare Before You Choose
Compare Hims on price, review history, and program fit.
A positive review is still a reason to compare before enrolling. Some links are compensated; editorial scores are independent.
| Provider | Published price | Trustpilot |
|---|---|---|
| WellMedr | From $49 – $129/mo | 4.6/5 (1,963) |
| Trimi | From $99 – $125/mo | Not listed |
| SkinnyRx | From $149 – $449/mo | 4.8/5 (5,335) |
Hims Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Hims.
| Program / Membership Fee | Included in monthly plan |
| Medication Cost (From) | From $149 – $499/mo |
Hims bundles provider visits, prescription, and shipping into a single monthly subscription. Compounded GLP-1 plans and brand-name medications are priced separately, with brand-name GLP-1s reflecting manufacturer list prices.
Who Hims Is For
Hims is best suited to buyers who want a recognizable, publicly traded telehealth platform with broad category coverage and no insurance hassles. The proprietary MedMatch personalization layer matters most to people who plan to stay on the platform across multiple conditions.
Adults who want one publicly traded telehealth brand for weight loss, ED, and hair loss under a single account.
Signature Programs
- ›Compounded GLP-1 weight loss
- ›Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro
- ›ED and hair-loss multi-category care
Medication Formulary
The Bottom Line
A high-volume operator with one of the widest formularies in telehealth, useful for buyers who want a single login across categories. Look elsewhere if you want a boutique clinic relationship or specialist-grade depth in any one vertical.
With an editor score of 4.5 / 5 across cost, experience, and trust, Hims is one of the top-tier options in the glp-1 weight loss category we cover.
See how Hims compares in our full glp-1 weight loss rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks in the STEP 1 trial.
- FDA Federal Register 2024 (Semaglutide shortage end) · FDA removed semaglutide from the drug shortage list in October 2024, ending the legal basis for compounding.
- Garvey et al., NEJM 2022 (STEP 5) · Two-year STEP 5 data confirmed sustained 15.2% weight loss with semaglutide 2.4 mg.
- Goldstein et al., NEJM 1998 (Sildenafil) · Pivotal NEJM trial establishing sildenafil efficacy: 69% of attempts successful vs 22% placebo.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1 -- tirzepatide) · Tirzepatide 15 mg produced 20.9% mean weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1.
- FDA Prescribing Information: sildenafil citrate (Viagra) · FDA-approved prescribing information for sildenafil citrate tablets, including dosing, contraindications, and drug interactions.
- Kaufman & Dawber, JAAD 1998 (finasteride 1 mg for androgenetic alopecia) · Finasteride 1 mg daily reduced scalp DHT by approximately 60% and significantly increased hair count vs placebo in men with male-pattern hair loss.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
How Hims Stacks Up
Alternatives To Hims
Hims does not currently offer a direct online intake. The providers below offer similar programs and are accepting new patients.
Also Competes With
Hims also operates in Erectile Dysfunction, Hair Loss. Here are other providers in those spaces: